ASCO: American Society of Clinical Oncology

A study finds limited changes in hospice utilization, highlighting challenges in real-world implementation.

A poster presented at the 2024 American Society of Clinical Oncology annual meeting argued the benefits that Medicaid expansion can bring to patients with melanoma.

The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.

Two posters presented at the 2024 American Society of Clinical Oncology annual meeting revealed real-world data on the outcomes and management strategies associated with melanoma during pregnancy.

This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

At the 2024 American Society of Clinical Oncology annual meeting, an abstract presenting real-world data stressed the need for further research regarding the association between immunosuppressant medication and the development of skin cancer.

One patient died during this study, which used PET/CT, flow cytometry, and next-generation sequencing to define measurable residual disease negativity.

The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.

The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.

Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy.

Several experts that we spoke with for ASCO 2024 share their thoughts on why the American Society of Clinical Oncology annual meeting is so important to the field of oncology.

Coverage of a session on antibody drug conjugates from the 2024 American Society of Clinical Oncology Annual Meeting.

In the final overall survival analysis of the phase 3 CARES-310 trial, frontline camrelizumab plus rivoceranib continued to show clinically meaningful survival benefits vs sorafenib for hepatocellular carcinoma (HCC).

The Alliance A091902 trial is currently investigating paclitaxel with and without nivolumab in patients who are taxane naive and nivolumab plus cabozantinib in taxane-pretreated patients.

This new analysis of nivolumab presented at ASCO 2024 shows the immune checkpoint inhibitor did not convery benefit when added to a regimen of neoadjuvant carboplatin, paclitaxel, and radiation.

An in-depth analysis of minimal residual disease (MRD) negativity results from the PERSEUS trial shows patients whose treatment regimen included subcutaneous daratumumab had responses that deepened over time.

Results for the first 10 patients offer promising signs for giving patients with multiple myeloma a prophylactic dose of tocilizumab before they are treated with the bispecifc antibody teclistamab.

The findings can help reduce barriers that delay the onset of recommended palliative care in advanced cancer.

The idea that patients could get better responses with shorter courses of therapy runs counter to the current standard of care in melanoma.

Within the GAIN-S model, geriatric care assessments among older patients with cancer are combined with care interventions, and it is delivered soon before patients have an intervention on their cancer therapy, says William Dale, MD, PhD, FASCO, City of Hope.

A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer.

The BE-a-PAL study investigated potential of an algorithm-based default palliative care referral among patients who have stage III or IV lung or noncolorectal gastrointestinal cancer.

Attendees packed a session on multicancer early detection (MCED) on the first day of the 2024 American Society of Clinical Oncology annual meeting.

The annual session on newly approved drugs reviewed adverse effects, mechanisms of action, and real-world experiences.

Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab for B-cell non-Hodgkin lymphoma, of which mantle cell lymphoma (MCL) is a rare type.

The TROPiCS-02 trial studied sacituzumab govitecan vs physician’s choice of chemotherapy for HR+/HER2– breast cancer.

Topics at the upcoming meeting of the American Society of Clinical Oncology include the impact of artificial intelligence and the best way to deliver palliative care.

In this interview ahead of the 2024 American Society of Clinical Oncology annual meeting (ASCO), Ravin Ratan, MD, MEd, The University of Texas MD Anderson Cancer Center, discusses study data he is excited to hear more about on the combination of trabectedin and low-dose irinotecan for relapsed/refractory Ewing sarcoma.

Two abstracts presented at the 2023 American Society of Clinical Oncology annual meeting evaluated biosimilar adoption across oncology practices and highlighted the role payers play in preventing or promoting adoption.